Research Progress of Immune Checkpoint Inhibitor-associated Myocarditis

Chinese Journal of Lung Cancer

Zhimin ZENG¹  Anwen LIU¹  Yunwei LIU¹  Yanxin CHEN¹ 

[1] Department of Oncology, The Second Affiliated Hospital of Nanchang University, 
Jiangxi Key Laboratory of Clinical Translational Cancer Research, Nanchang 330006, China;

关键词: immune checkpoint inhibitor;    myocarditis;    cardiotoxicity;   

DOI  :  10.3779/j.issn.1009-3419.2021.102.27

来源: DOAJ

【 摘 要 】

Immune checkpoint inhibitors (ICIs) is a negative regulatory factor antibody, which activates T cells to play an anti-tumor effect in immunotherapy, and can also cause immune-related adverse responses, thereby inducing a series of immune related adverse events (irAEs). Among these irAEs, although the incidence of ICIs-related myocarditis is very low, the fatality rate is significantly higher than other adverse reactions, close to 50%. Clinicians should be vigilant when applying ICIs, but the pathogenesis of ICIs-related myocarditis is still unclear. This article combines the recent research results of ICIs to summarize the mechanism and clinical manifestations of ICIs-related myocarditis, so as to improve clinicians' understanding of the adverse reactions.

【 授权许可】

Unknown